Back to search results

Personalized Drug Screening for Newly Diagnosed Glioblastoma

This study is testing a new way to treat newly diagnosed glioblastoma (a type of brain cancer). Researchers will take cells from your tumor and test them with combinations of up to three FDA-approved drugs to find the best personalized treatment for you. This personalized drug combination will be given along with standard treatments like radiation and TMZ (temozolomide). The main goal is to see how safe this personalized drug approach is. You may be able to join if you are 18 or older, have newly diagnosed glioblastoma that can be surgically removed, and have a life expectancy of more than 6 months. The study is currently recruiting participants.

Study design
This is an interventional study with a planned enrollment of 10 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored from the first dose of the study drug until your cancer progresses or you pass away, for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05380349

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
Swedish Medical Center
~10 participants
Updated 2025-05-16 on ClinicalTrials.gov
What's tested:combinations of up to 3 FDA approved drugs from a panel of compounds

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
determine safety of CSC/HTS-based combination drug therapy
Measured over From date of first dose of investigational drug regimen until date of first documented progression or death from any cause, whichever came first, assessed up to 24 months.

Conditions

Newly Diagnosed Glioblastoma

Explore related trials

Glioblastoma

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Charles S Cobbs · PRINCIPAL_INVESTIGATOR · Ivy Center for Advanced Brain Tumor Treatment

Who to contact

Charles S Cobbs, M.D.
[email protected]
206-320-2300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histological diagnosis of GBM (WHO grade 4)
Subjects ≥18 years of age
Patients must have a life expectancy of \>6 months
Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)
Patients must have a KPS rating of ≥70
Patients should not have received any prior systemic anti-cancer therapy
Patients must be negative for HIV, Hepatitis B and C
Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:
Hemoglobin (Hgb)\> 8 g/dL
Absolute Neutrophil Count (ANC) \> 1,000/mm3
Platelet count \> 100,000/mm3
Creatinine \< 2 mg/dL
Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \< 3x upper limit of normal (ULN)

Exclusion

Metastatic disease
Diseases or conditions that obscure toxicity or dangerously alter drug metabolism
Serious intercurrent medical illness
Inadequately controlled hypertension
History of myocardial infarction or unstable angina within 6 months
History of stroke or transient ischemic attack within 6 months

What this trial measures

  • determine safety of CSC/HTS-based combination drug therapyFrom date of first dose of investigational drug regimen until date of first documented progression or death from any cause, whichever came first, assessed up to 24 months.

    incidence of treatment-related AEs, laboratory abnormalities, and SAEs as assessed by CTCAE version 5.0